First Light Biosciences Announces New Corporate Headquarters in Chelmsford, Massachusetts
New facility offers additional space, state of the art laboratory, added manufacturing capacity
CHELMSFORD, Mass., Dec. 5, 2018 /PRNewswire/ -- First Light Biosciences, a developer of breakthrough automated diagnostic products for rapid, sensitive, and cost-effective diagnostic tests for life-threatening infections, today announced its recent move to a new corporate headquarters in Chelmsford, Massachusetts. The move provides additional space needed to support the company's continued growth.
The new headquarters is conveniently located at the intersection of two major highways, offering a more direct commute for employees and streamlined logistics capabilities. At double the space, the facility includes a state-of-the-art laboratory to enable accelerated product development of the MultiPath™ platform. In addition, the environmental-controlled manufacturing space delivers added capacity and capabilities with room for additional growth.
"Our new facility creates the perfect space for us to showcase our products and create a work environment for employees that promotes innovation, collaboration, and fun," said David Macdonald, CEO of First Light Biosciences. "As we move to the next phase in our company evolution, this location will not only be a showplace but an employment destination for some of the best and brightest in the industry."
First Light Biosciences new headquarters' address is:
2 Omni Way
Chelmsford, MA 01824
781-271-0112
About First Light Biosciences
First Light Biosciences is developing and preparing to commercialize, innovative diagnostic products for rapid, sensitive and cost-saving detection of life-threatening infections, and combating the spread of antibiotic resistance. Don Straus is the company's Founder and primary inventor of the company's core scientific technology. Based on its proprietary MultiPath™ detection technology, First Light's products combine the clinical performance of the most advanced commercial laboratory tests with speed, cost-effectiveness, and ease-of-use. The tests rapidly detect infections, identify infectious agents, and determine effective targeted antibiotic therapy. This will improve patient outcomes, reduce healthcare costs, and prevent inappropriate use of powerful antibiotics. To learn more, please visit: www.firstlightibio.com
Public relations contact:
David Macdonald
President and CEO
First Light Biosciences
[email protected]
Mobile: (858) 997-9641
SOURCE First Light Biosciences
Share this article